Ultragenyx Pharmaceutical(US:RARE) TMX Newsfile·2026-02-14 03:21Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. for the period between August 3, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's drug setrusumab [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx provided investors with overly positive information about the expected results of its Phase III Orbit and Cosmic Studies for setrusumab, which is intended for treating Osteogenesis Imperfecta (OI) [5]. - Defendants allegedly made materially false and misleading statements about setrusumab's potential, claiming it would decrease the annualized fracture rate in OI patients, while concealing the true risks and limitations of the study protocols [6]. - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the true information became public [6]. Group 2: Participation in the Class Action - Investors who purchased Ultragenyx common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. - A lead plaintiff must be appointed by April 6, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].